Search company, investor...
MabVax Therapeutics company logo

MabVax Therapeutics


Reverse Merger | IPO

Total Raised


About MabVax Therapeutics

MabVax Therapeutics is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer. MabVax is creating a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Headquarters Location

11588 Sorrento Valley Road Suite 20

San Diego, California, 92121,

United States


Missing: MabVax Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MabVax Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MabVax Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MabVax Therapeutics is included in 1 Expert Collection, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

MabVax Therapeutics Patents

MabVax Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Immunology, Immune system, Clusters of differentiation, Molecular biology


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Immunology, Immune system, Clusters of differentiation, Molecular biology



Latest MabVax Therapeutics News

Unituxin Patent, Sales & Clinical Trials Guide 2021-2028, Featuring Bellicum Therapeutics, MabVax Therapeutics, Sinobioway Cell Therapy and United Therapeutic Corporation

Nov 26, 2021

Neuroblastoma is an embryonic cancer of the post-ganglionic sympathetic nervous system. The treatment with conventional cancer therapies are associated with poor survival outcomes, thus posing high medical needs for the development of targeted therapies. Genomic analysis of neuroblastoma has revealed high expression of GD2 on cancer cells. Owing to its restricted expression in normal cells, targeting GD2 has proven to be effective for the treatment of cancer. Researchers have developed GD2 targeting antibodies which work by targeting GD2 receptor on cancer cells. Unituxin (dinutuximab) is first approved disialoganglioside, GD2-binding chimeric monoclonal antibody. The drug was developed by United Therapeutics Corporation and is indicated for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Owing to its targeted mechanism of action, the drug has shown high adoption rates in the market. The drug was also approved in Europe, but it was later discontinued due to short- and intermediate- term inability to supply Unituxin in sufficient quantities for meeting current global demands. Recently, scientists have also developed dinutuximab beta which is another version of dinutuximab. The dinutuximab was developed is manufactured using mouse cells, whereas dinutuximab beta is manufactured using hamster cells. Following withdrawal of Unituxin, European Medicines Agency has rapidly approved Qarbiza (dinutuximab beta) for the treatment of neuroblastoma. More recently, China National Medical Products Administration (NMPA) has granted Qarbiza conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above. Currently the drug Unituxin is mainly indicated for the management of neuroblastoma. However, ongoing clinical trials are also evaluating the role of these drugs in the treatment of other cancers also including osteosarcoma and small cell lung cancer. In addition, several ongoing clinical trials are also evaluating the role of drug in combination with other cancer targeting regimens. The coming years will witness rapid approval of drug as monotherapy or combinational therapy in wide range of cancers, which will further propel the growth of market during the forecast period. As per report findings, the global Unituxin market is currently present at nascent stage and will grow slow growth rates during the forecast period. Several factors including increase in prevalence of cancer, no competition from generic drugs, rising awareness about the availability of drug and robust sales of Unituxin in global market will boost the growth of market. In addition to this, the high adoption rates of novel therapy as well as rising initiative by government to initiate research and development activities will also drive the future of the market. In addition, it will also face competition from novel emerging GD2 taregting drugs which are expected to enter the market during forecast period. Presently, US holds the top position in the market and is expected to maintain its position during the forecast period due to to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development. In addition to this, the rise in prevalence of cancer and the increase awareness for the acceptance of novel therapies is also going to drive the future of the market. Moreover, the global market will be driven the rising approval of these drugs in other regions such as Europe, China and Asia and their increasing applications in other cancers. The report provides detailed analysis on Unituxin including its price, sales, dosage, and clinical trial insights. On the basis of this, the future sales of the drug have been forecasted and market opportunity of drug in neuroblastoma as well as small cell lung cancer has been established. Unituxin Patent, Sales & Clinical Trials Outlook 2028 Report Analysis & Data Highlights: Unituxin Patent Insight Unituxin Role in Cancer Therapy Unituxin Structure & Pharmacokinetics Properties Unituxin Reimbursement Scenario

MabVax Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MabVax Therapeutics Rank

MabVax Therapeutics Frequently Asked Questions (FAQ)

  • Where is MabVax Therapeutics's headquarters?

    MabVax Therapeutics's headquarters is located at 11588 Sorrento Valley Road, San Diego.

  • What is MabVax Therapeutics's latest funding round?

    MabVax Therapeutics's latest funding round is Reverse Merger.

  • How much did MabVax Therapeutics raise?

    MabVax Therapeutics raised a total of $30.5M.

  • Who are the investors of MabVax Therapeutics?

    Investors of MabVax Therapeutics include Telik, National Cancer Institute, Biomark Capital and Numoda Capital Innovations.

  • Who are MabVax Therapeutics's competitors?

    Competitors of MabVax Therapeutics include GeoVax, Scancell, Aquinox Pharmaceuticals, ImmunoReagents, Igenica Biotherapeutics, Forte Biosciences, U3 Pharma, 4-Antibody, KAI Pharmaceuticals, Cylene Pharmaceuticals and 14 more.

Compare MabVax Therapeutics to Competitors


NanoMedica aims to become engaged in design,development and manufacture of dual-action therapeutics for the treatment of human cancer.

Alligator Bioscience

Alligator Bioscience discovers and develops antibody-based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span early research phases with lead identification up to proof of concept phase I/II clinical studies in cancer patients.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Ascent Therapeutics

Ascent Therapeutics is a biopharmaceutical company developing a approach to the treatment of human disease that rapidly generates pharmaceuticals critical to many disease processes.

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Oxford Genome Sciences (UK)

Oxford BioTherapeuticsis focused on the targeted treatment of cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.